Supplementary Figure 1 from Novel Chemosensitive Single-Nucleotide Polymorphism Markers to Targeted Regimens in Metastatic Colorectal Cancer

Autor:	Yong S. Kim, Hyoungseok Ju, Tae W. Kim, Seon A. Roh, Chan W. Kim, Eun Y. Choi, Ye J. Ha, Dong H. Cho, Seon Y. Kim, Jin C. Kim
Rok vydání:	2023
DOI:	10.1158/1078-0432.22444835
Popis:	PDF file - 376K, Inhibition rates (IR) of tumor growth (A) and response rates at IR30 (chemosensitivity) (B). The IRs and IR30 of a single bevacizumab or cetuximab regimen were significantly less than those of the other four combination regimens (P � 0.001). IR, inhibition rate; FRB, FOLFIRI + bevacizumab; FXB, FOLFOX + bevacizumab; FRC, FOLFIRI + cetuximab; FXC, FOLFOX + cetuximab.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a473ba7dea4671299522a34854e2ed29 https://doi.org/10.1158/1078-0432.22444835 Zobrazit plný text záznamu